In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Statistics Quarterly, Q1 2006

Executive Summary

In this issue, we present another installment of our quarterly review of dealmaking-for January-March 2006. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.

You may also be interested in...



Angiotech acquires Device Company, Takes Control of its Destiny

Ever since drug-eluting stents became such an overwhelming success, the health care products industry has been trying to wrap its arms around convergence opportunities, in which the combination of drugs and devices is worth more than the sum of the parts and pieces. The ongoing debate has been: which part of combination products is it better to own--the drug or the device? According to one company that would probably define itself as the only "pure play" in convergence, Angiotech Pharmaceuticals Inc., the answer is: both. Angiotech just acquired diversified device manufacturer AMI Holdings.

Teva/Ivax: Generics' Answer to Big Pharma

Bigger generics companies aren't just the generic sector's problem. Giants such as the new Teva will present more formidable challenges to innovators, not just in patent wars but also with proprietary launches, and for a share of drug consumption in developing markets.

Pfizer Oncology Pipeline Shows Pivot To Targeted Therapies

Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel